Allovectin fails Phase III trial for Melanoma
Vical Incorporated has announced top-line results from a Phase III trial of Allovectin-7 (velimogene aliplasmid), an investigational intratumoral cancer immunotherapy, in patients with Metastatic Melanoma. The 390-subject trial failed to demonstrate a statistically significant improvement vs. first-line chemotherapy for either the primary endpoint of objective response rate at 24 weeks or more after randomization or the secondary endpoint of overall survival. Trial data will be further analysed and detailed results will be submitted for publication.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.